Lipella Pharmaceuticals Inc
LIPO2.360USD
-0.345-12.75%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
6.02MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Lipella Pharmaceuticals Inc Unternehmen
Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Its lead product candidates include LP-10, LP-310 and LP-410. LP-10 is the development name of its reformulation of tacrolimus specifically optimized for topical deposition to the internal surface of the urinary bladder lumen using a proprietary drug delivery platform. LP-310 is the development name of its oral, liposomal formulation of tacrolimus specifically optimized for local delivery to oral mucosa. It is also developing an oral, liposomal formulation of tacrolimus, LP-410, for the treatment of oral graft-versus-host disease (GVHD). LP-410 is an oral rinse, like LP-310, but has a different containment system. LP-410 targets the underlying mechanisms of oral GVHD, potentially providing a safe and effective treatment option for affected individuals.
Unternehmensinformationen
BörsenkürzelLIPO
Name des UnternehmensLipella Pharmaceuticals Inc
IPO-datumDec 20, 2022
CEODr. Jonathan H Kaufman, Ph.D.
Anzahl der mitarbeiter5
WertpapierartOrdinary Share
GeschäftsjahresendeDec 20
Addresse400 N Lexington St Ste LL103
StadtPITTSBURGH
BörseUS 'Other OTC' and Grey Market
LandUnited States of America
Postleitzahl15208
Telefon14129010315
Websitehttps://lipella.com/
BörsenkürzelLIPO
IPO-datumDec 20, 2022
CEODr. Jonathan H Kaufman, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jonathan H Kaufman, Ph.D.
Dr. Jonathan H Kaufman, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Treasurer, Secretary
Chairman of the Board, President, Chief Executive Officer, Treasurer, Secretary
112.35K
--
Dr. Micheal B. Chancellor
Dr. Micheal B. Chancellor
Chief Medical Officer, Director
Chief Medical Officer, Director
--
--
Dr. Byeong (Christopher) Kim, Ph.D.
Dr. Byeong (Christopher) Kim, Ph.D.
Independent Director
Independent Director
--
--
Dr. Lori A. Birder, Ph.D.
Dr. Lori A. Birder, Ph.D.
Independent Director
Independent Director
--
--
Mr. Douglas Johnston, CPA
Mr. Douglas Johnston, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Naoki Yoshimura, M.D., Ph.D.
Dr. Naoki Yoshimura, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Chuck Harbey
Mr. Chuck Harbey
IR Contact Officer
IR Contact Officer
--
--
Mr. Daniel Cohen
Mr. Daniel Cohen
Independent Director
Independent Director
--
--
Mr. Ryan Pruchnic
Mr. Ryan Pruchnic
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jonathan H Kaufman, Ph.D.
Dr. Jonathan H Kaufman, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Treasurer, Secretary
Chairman of the Board, President, Chief Executive Officer, Treasurer, Secretary
112.35K
--
Dr. Micheal B. Chancellor
Dr. Micheal B. Chancellor
Chief Medical Officer, Director
Chief Medical Officer, Director
--
--
Dr. Byeong (Christopher) Kim, Ph.D.
Dr. Byeong (Christopher) Kim, Ph.D.
Independent Director
Independent Director
--
--
Dr. Lori A. Birder, Ph.D.
Dr. Lori A. Birder, Ph.D.
Independent Director
Independent Director
--
--
Mr. Douglas Johnston, CPA
Mr. Douglas Johnston, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Naoki Yoshimura, M.D., Ph.D.
Dr. Naoki Yoshimura, M.D., Ph.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, May 17
Aktualisiert: Sat, May 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Kaufman (Jonathan H)
2.51%
Chancellor (Michael B.)
2.46%
Huang (Leaf)
1.55%
Sabby Management, LLC
1.35%
Tower Research Capital LLC
0.06%
Other
92.06%
Aktionäre
Aktionäre
Anteil
Kaufman (Jonathan H)
2.51%
Chancellor (Michael B.)
2.46%
Huang (Leaf)
1.55%
Sabby Management, LLC
1.35%
Tower Research Capital LLC
0.06%
Other
92.06%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
6.52%
Investment Advisor/Hedge Fund
1.35%
Hedge Fund
0.06%
Other
92.06%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
17
354.66K
7.94%
+95.32K
2025Q1
17
354.67K
11.68%
+95.33K
2024Q4
18
368.12K
30.45%
+2.26K
2024Q3
16
304.96K
29.23%
-126.37K
2024Q2
16
428.52K
49.20%
+108.86K
2024Q1
16
431.88K
52.07%
+138.44K
2023Q4
14
329.34K
44.74%
+70.35K
2023Q3
12
252.11K
34.85%
+66.33K
2023Q2
13
302.02K
42.06%
+116.08K
2023Q1
12
303.82K
42.31%
+124.35K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Kaufman (Jonathan H)
112.35K
2.51%
-4.00
-0.00%
Apr 09, 2025
Chancellor (Michael B.)
109.70K
2.46%
--
--
Apr 09, 2025
Huang (Leaf)
69.44K
1.55%
+60.76K
+700.03%
Mar 31, 2025
Sabby Management, LLC
60.33K
1.35%
+60.33K
--
Dec 31, 2024
Tower Research Capital LLC
2.71K
0.06%
+2.71K
--
Mar 31, 2025
MAI Capital Management, LLC
125.00
0%
--
--
Mar 31, 2025
BofA Global Research (US)
7.00
0%
--
--
Mar 31, 2025
Virtu Americas LLC
--
0%
-13.31K
-100.00%
Mar 31, 2025
HRT Financial LP
--
0%
-2.20K
-100.00%
Dec 31, 2024
Geode Capital Management, L.L.C.
--
0%
-3.11K
-100.00%
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Nov 01, 2024
Merger
8<1
Nov 01, 2024
Merger
8<1
Nov 01, 2024
Merger
8<1
Nov 01, 2024
Merger
8<1
Datum
Art
Verhältnis
Nov 01, 2024
Merger
8<1
Nov 01, 2024
Merger
8<1
Nov 01, 2024
Merger
8<1
Nov 01, 2024
Merger
8<1
